Solid Biosciences Announces Inducement Grant per Nasdaq Rule 5635(c)(4)

Solid Biosciences Inc., a life sciences company listed on Nasdaq under the symbol SLDB, is making strides in the development of precision genetic medicines for neuromuscular and cardiac diseases. On July 1, 2024, the company announced the grant of 11,847 restricted stock units (RSUs) to a newly hired employee. These RSUs will vest in four equal parts annually over four years, contingent upon the employee's continued service with the company.

The RSU grant is part of Solid Biosciences' 2024 Inducement Stock Incentive Plan and was specifically designed to attract new talent, in line with Nasdaq Listing Rule 5635(c)(4).

Solid Biosciences has a focused portfolio of gene therapy candidates aimed at treating various severe conditions. Among these are SGT-003, targeting Duchenne muscular dystrophy (Duchenne), and SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT). Other notable candidates include AVB-401 for BAG3-mediated dilated cardiomyopathy and additional projects aimed at treating fatal cardiac diseases.

The company is committed to advancing its pipeline of treatments for rare neuromuscular and cardiac diseases, leveraging expertise in science, technology, disease management, and patient care. Solid Biosciences was founded by individuals directly affected by these conditions, and it maintains a strong patient-focused approach, aiming to improve the daily lives of those suffering from these debilitating diseases.